# Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

> **NCT07454031** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 22 (estimated)

## Conditions studied

- Peritoneal (Metastatic) Cancer

## Interventions

- **DRUG:** intraperitoneal PX in combination with nab-paclitaxel

## Key facts

- **NCT ID:** NCT07454031
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454031, "Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07454031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*